|Day Low/High||7.37 / 7.56|
|52 Wk Low/High||6.95 / 13.91|
The Medical Technology Stock Letter's top pick rose 357% in 2019.
The indices moved into positive territory and now the action has cooled off.
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Market players are more skeptical of the quick moves on U.S.-China trade news.
Let's take a look at the charts and indicators.
From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.
Despite $5.1 billion deal for Costa, I'm not slurping any KO up.
You don't have to be Sigmund Freud to understand the psychology here.
I expect CRM to regain its footing quickly and challenge highs again soon.
If estimates continue to come up there will be institutional interest in the stock.
Apple in particular is helping the bullish cause.
Sentiment is very positive, regardless of what the indices may say.
In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.
There is no question that we are becoming extended and ripe for some profit taking.
The game plan is to spot the charts that have more room to run.
Wall Street discounting talk of bombing Syria from president.
Whether this market continues to bounce is going to depend a great degree on the FAANG names.
Many stocks are already at support levels and are offering opportunities to start some positions.
4 stocks on my shopping list for when conditions improve.
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
It's hard to believe the bounce will continue to run in V-shaped fashion.
It is a very different market environment now which can be very rewarding depending on your style.
If we have a little consolidating action here the buyers will start pushing again.
There are signs of stabilization, but the market is still digesting some very big swings.
The volatility trade that propped up markets is no longer available.
It would be a longer-term positive if the overbought conditions are alleviated.
What drives the trading action are structural issues, not macroeconomic news events or political drama.
There is still a very strong appetite for individual stocks with momentum.